Severe, Therapy-Resistant Generalized Lichen Sclerosus with Morphea Overlap Successfully Treated with Intravenous Immunoglobulin and Type 1 Interferon Receptor Monoclonal Antibody Infusion: A Case Report. (PubMed, Case Rep Dermatol) - Sep 23, 2026 - "Conventional first-line and extended immunomodulatory or immunosuppressive treatments, including potent topical corticosteroids, UVA-1 phototherapy, extracorporeal photopheresis, methotrexate, hydroxychloroquine, multiple biologics, and JAK inhibitors, showed little sustained benefit and were sometimes associated with deterioration or relevant immunosuppression. In severe therapy-refractory lichen sclerosus-morphea overlap, combined IVIG, rituximab, and anifrolumab may help control skin inflammation, sclerosis, and skin ulceration. This case supports cytokine-guided, mechanism-based salvage therapy in selected therapy-refractory patients."
Journal • Dermatitis • Dermatology • Fibrosis • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease • Pain • Ulcerative Colitis • CXCL10 • CXCL9 • IFNAR2 • IL18
|
|
Abdulaziz Alhowaish; Antonios G A Kolios; Dieter O Mayer; Fayez Alotaibi; Hans Ulrich Gerth; Jivko Kamarachev; Jürg Hafner; Myriam Hofer
|